Stenotrophomonas maltophilia an Emerging Opportunistic Bacterial Infection Isolated from Diverse Clinical Samples

Puneeta Singh^1, , Shalabh Malik¹ and Vandana Lal²

¹Department of Microbiology and Serology, Dr Lal Path Labs, National Reference Laboratory, Delhi, India

²Dr Lal Path Labs, National Reference Laboratory, Delhi, India

Cite this paper:
Puneeta Singh, Shalabh Malik and Vandana Lal. Stenotrophomonas maltophilia an Emerging Opportunistic Bacterial Infection Isolated from Diverse Clinical Samples. American Journal of Microbiological Research. 2022; 10(2):50-54. doi: 10.12691/ajmr-10-2-1

Abstract

Aim: The aim of this study was to assess the prevalence of infection, antimicrobial susceptibility pattern of Stenotrophomonas maltophilia in diverse samples in the Delhi. Materials and Methods: This is a retrospective study conducted over a period of three years, i.e., January 2019 to December 2021. All clinical samples received in the microbiology laboratory at Dr Lal Path Labs, Delhi during the study period were processed using standard microbiological procedures. Antibiotic susceptibility was performed for Levofloxacin, Minocycline and Trimethoprim-sulfamethoxazole by Vitek 2 system (bioMerieux, India) as per CLSI guidelines. Results and Discussion: A total of 9615 non fermenters were isolated, among the non-fermenters, 375 (3.9%) were Stenotrophomonas maltophilia. The most prevalent source of S. maltophilia was largely isolated from blood (34.7%) followed by fluids (20.3%), respiratory (17.8%) and other specimens. This study highlighted potency and the limitation of available agent in the era of antibiotic resistance especially in Delhi, India. Our study describes the distribution and antibiotic resistance of Levofloxacin, Trimethoprim-sulfamethoxazole and Minocycline based on cumulative interpretation and MIC across all age groups. Conclusion: The Stenotrophomonas maltophilia isolates collected in our study had relatively high susceptibility to Minocycline, good susceptibility to Trimethoprim/sulfamethoxazole, but low susceptible to Levofloxacin. Minocycline, could be useful alternative treatment options in Trimethoprim/sulfamethoxazole and Levofloxacin resistant strains.

Keywords:
Stenotrophomonas maltophilia (S. maltophilia) Trimethoprim/sulfamethoxazole (TM/SXT) minocycline Levofloxacin (LVX) non fermenters nosocomial

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Alsuhaibani M, Aljarbou A, Althawadi S, Alsweed A & Al-Hajjar S. Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate. Antimicrob Resist Infect Control. 2021; 10:19.
[2]	Anthony A. Adegoke, Stenström TA and Okoh A I. Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking beyond Contemporary Antibiotic Therapy. Front. Microbiol. 2017.
[3]	Behera B. Stenotrophomonas maltophilia, an emerging pathogen in newborns: Three case reports and a review of the literature. World J Clin Infect Dis. 2021; 11(1): 11-18.
[4]	Biagi M, Tan X, Wu T, Jurkovic M, Vialichka A, Meyer K, et al. Activity of potential alternative treatment agents for Stenotrophomonas maltophilia isolates nonsusceptible to levofloxacin and/or trimethoprim-sulfamethoxazole. J Clin Microbiol. 2020; 58:e01603-19. (Minocycline sensitive).
[5]	Brooke JS. Stenotrophomonas maltophilia: An Emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25:2-41.
[6]	Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front. Microbiol. 2015.
[7]	Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY., et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J. Korean Med. Sci. 2013; 28, 62-66.
[8]	Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing. M100‑S31. Wayne, PA: CLSI; 2021.
[9]	Gajdacs M and Urban E. A 10 year single center experience on Stenotrophomonas Maltophilia resitotyping in Szeged, Hungry. Eur J Microbiol Immunol. 2020; 18; 10(2): 91-97.
[10]	Gil-Gil T, Martinez JL and Blanco P. Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge.Expert Rev Anti Infect Ther. 2020; 18(4): 335-347.
[11]	Gokhan GM, Celik C, Elaldi N. Stenotrophomonas maltophilia Infections in Adults: Primary Bacteremia and Pneumonia, Jundishapur J Microbiol. 2015; 8(8):e23569.
[12]	Gupta P, Kale P, Khillan V. Resurgence of global opportunistic multidrug-resistant Stenotrophomonas maltophilia. Indian J Crit Care Med. 2018; 22: 503-8.
[13]	Insuwanno W, Kiratisin P, Jitmuang A. Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients. Infection and Drug Resistance. Infect Drug Resist. 2020; 13: 1559-1566.
[14]	Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: An emerging opportunistic human pathogen. Lancet Infect Dis. 2009; 9: 312-23.
[15]	Nayyar C, Thakur P, Tak V, and Saigal K. Stenotrophomonas maltophilia: An Emerging Pathogen in Paediatric Population. J Clin Diagn Res. 2017; 11(1): DC08-DC11.
[16]	Sader, HS, Flamm RK, and Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn. Microbiol. Infect. Dis. 2013; 76, 217-221.
[17]	Soumya JS, Kabbin JS, Ambica R. Stenotrophomonas maltophilia: An emerging pathogen in sepsis. MRIMS J Health Sci. 2020; 8: 64-7.
[18]	Sattler CA, Mason EO, Kaplan SL, Nonrespiratory Stenotrophomonas maltophilia Infection at a Children's Hospital, Clinical Infectious Diseases. 2000. 31 (6): 1321-1330.